Abstract Efficient delivery of payload to intracellular targets has been identified as the central principle for nanomedicine development, while the extracellular targets are equally important for cancer treatment. Notably, the contribution of extracellularly distributed nanoparticles to therapeutic outcome is far from being understood. Herein, we develop a pH/light dual-responsive monochromatic ratiometric imaging nanoparticle (MRIN), which functions through sequentially lighting up the intracellular and extracellular fluorescence signals by acidic endocytic pH and near-infrared light. Enabled by MRIN nanotechnology, we accurately quantify the extracellular and intracellular distribution of nanoparticles in several tumor models, which account for 65-80% and 20-35% of total tumor exposure, respectively. Given that the majority of nanoparticles are trapped in extracellular regions, we successfully dissect the contribution of extracellularly distributed nanophotosensitizer to therapeutic efficacy, thereby maximize the treatment outcome. Our study provides key strategies to precisely quantify nanocarrier microdistribtion and engineer multifunctional nanomedicines for efficient theranostics.
Introduction
In nanomedicine, delivery efficiency is often reported as a single macroscopic value. However, the tumor microenvironment is a complex landscape where nanoparticles either enter cancer cells (intracellular) or remain sequestered in the surrounding structural matrix (extracellular). While most research focuses on increasing cellular uptake for intracellular targets like DNA, two major gaps persist: the inability to quantify this distribution in real-time in living subjects, and the perception of extracellular nanoparticles as "wasted" dose. This study introduces Monochromatic Ratiometric Imaging Nanoparticles (MRIN) to bridge these gaps, quantifying microdistribution and leveraging the extracellular fraction for enhanced therapy.
The MRIN Mechanism
MRINs are micelles composed of ultra-pH-sensitive (UPS) polymers dual-labeled with a fluorophore (Cy5) and a quencher (Cy7.5). The system operates through sequential activation triggers:
- Intracellular Activation: Upon endocytosis, the acidic environment of the endosome (pH ~6.0) causes the micelle to dissociate. This separates the Cy5 from the Cy7.5 quencher, turning the fluorescence signal ON.
- Extracellular Activation: Particles remaining in the neutral pH of the extracellular space stay OFF. To visualize them, an 808 nm near-infrared (NIR) laser is applied to photobleach the Cy7.5 quencher, subsequently turning the remaining extracellular Cy5 signal ON.
By comparing images before and after the laser pulse, researchers can perform ratiometric analysis to calculate the exact distribution of the particles.
Quantifying the "80/20" Reality
Using five different tumor models (including 4T1 breast cancer and CT26 colon carcinoma), the MRIN system provided a precision map of nanoparticle distribution. The findings revealed a significant "Quantification Gap": the vast majority of nanoparticles (65–80%) never enter the cancer cells, remaining trapped in the acellular tumor stroma. Intracellular exposure accounts for only 20–35% of total tumor exposure.
Therapeutic Impact and Metastasis Inhibition
To utilize the "wasted" extracellular fraction, the researchers developed a therapeutic version (MRITN) using the photosensitizer Chlorin e6 (Ce6). Activating both compartments for Photodynamic Therapy (PDT) proved significantly more potent than intracellular-only treatment. The combined therapy achieved 94.5% tumor growth inhibition in 4T1 mouse models, compared to 52.2% for standard intracellular-targeted PDT.
Crucially, extracellular PDT was found to downregulate integrin β1, a protein essential for cell adhesion. This trigger induced anoikis—programmed cell death due to detachment—effectively preventing cancer cells from migrating and forming lung metastases.
Conclusion
This study provides a robust strategy to precisely quantify nanocarrier microdistribution in vivo. By demonstrating that the majority of nanoparticles reside extracellularly and showing that these particles can be activated to drive potent therapeutic responses and block metastasis, this work offers a new paradigm for engineering multifunctional nanomedicines.
Summary updated